Whereas Equity Crowdfunding isn’t yet legal in North America the movement is going to the next level in Europe! And its a significant step forward for this young financial model looking for a track record validating the concept: “The WORLD PREMIER successful EXIT for +200 CROWDFUNDERS”. It happened in France, for the biotech startup ANTABIO, via the equity crowdfunding platform called WISEED.com, on September 2012.
ANTABIO is a French biotech start-up dedicated to the discovery of novel drugs to treat and prevent antibiotic-resistant bacterial infections. ANTABIO’s novel compounds block the drug-resistance mechanisms and the virulence of pathogenic bacteria by targeting key bacterial pathways. The company was founded in 2009, in the Toulouse area, by Marc Lemonnier, CEO and Aymeric Dugray, CFO.
WISEED.com is a pioneering French equity crowdfunding platform, born in 2008. It allows individual investors to fund innovative start-up. With a few clicks, each private investor can become a shareholder of selected companies, starting from 100€. Since its inception the platform has helped 20 start-ups raising a total of €3 million.
The crowd who invested +300 k€ in ANTABIO was composed of 207 private investors based in France.
> EXCLUSIVE interview from Marc Lemonier (Antabio’s CEO)!
Here is an illustrated overview of that deal:
To be clear, Bruno who invested €1400 on December 2010 received €2434 on his bank account in September 2012. A +70% net capital gain within 20 months.
By itself this world premier successful deal doesn’t answer all questions about equity crowdfunding. However it could be used as an important case study for the futur, teaching us what seems to be key factors for entrepreneurs to successfully raise money from the crowd!